- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04356729
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma.
The names of the study drugs involved in this study are:
- Atezolizumab
- Bevacizumab
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved atezolizumab for this specific disease but it has been approved for other uses. The U.S. Food and Drug Administration (FDA) has not approved bevacizumab for this specific disease but it has been approved for other uses.
Atezolizumab and bevacizumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells and stop the growth of cancer. Atezolizumab and bevacizumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Elizabeth Buchbinder, MD
- Phone Number: 617-632-6588
- Email: Elizabeth_buchbinder@dfci.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Dana Farber Cancer Institute
-
Contact:
- Elizabeth I Buchbinder, MD
- Phone Number: 617-632-6704
- Email: Elizabeth_buchbinder@dfci.harvard.edu
-
Principal Investigator:
- Elizabeth I Buchbinder, MD
-
Boston, Massachusetts, United States, 02215
- Not yet recruiting
- Beth Israel Deaconess Medical Center
-
Principal Investigator:
- David F McDermott, MD
-
Contact:
- David F. McDermott, MD
- Phone Number: 617-632-9250
-
Boston, Massachusetts, United States, 02214
- Not yet recruiting
- Massachusetts General Hospital
-
Contact:
- Ryan Joseph Sullivan, MD
- Email: rsullivan7@partners.org
-
Principal Investigator:
- Ryan Joseph Sullivan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must have histologically or cytologically confirmed metastatic or unresectable stage III or IV cutaneous melanoma.
- PD-L1 negative staining in at least one biopsy sample.
- Age ≥ 18 years
- ECOG performance status ≤ 2 (Karnofsky ≥60%, see Appendix A)
- Participants may have received any number of prior therapies for treatment of their cutaneous melanoma, excluding prior treatment with anti-PD-L1 therapeutic antibodies or bevacizumab.
- Participants must have measurable disease per RECIST v1.1.
- Participants must have availability of a representative tumor specimen for exploratory biomarker research.
Participants must have normal organ and marrow function as defined below:
- lymphocyte count ≥ 500/mcL
- absolute neutrophil count ≥ 1,500/mcL without granulocyte colony-stimulating factor support
- platelets* ≥100,000/mcL
- hemoglobin* ≥9 g/dL
- serum bilirubin ≤1.5 x ULN with the following exception: participants with known Gilbert's Disease: serum bilirubin level ≤ 3x ULN
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN, with the following exceptions: Participants with documented liver metastases: AST and ALT ≤ 5 x ULN
- alkaline phosphatase (ALP) ≤2.5 × institutional ULN, with the following exceptions:
- participants with documented liver or bone metastases: ALP ≤ 5 x ULN
- serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
- serum albumin ≥ 2.5 g/dL
- For participants not receiving therapeutic anticoagulation: INR or aPTT ≤1.5 ULN
- Urine dipstick for proteinuria < 2+ (within 7 days prior to Cycle 1 Day 1). Participants discovered to have ≥ 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours. Note: Participants cannot be transfused to meet this criterion
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the last dose of atezolizumab, and 6 months after the last dose of bevacizumab.
- Examples of contraceptive methods with a failure rate of < 1 % per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 5 months after the last dose of atezolizumab and 6 months after the last dose of bevacizumab, to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Participants with symptomatic, untreated, or actively progressing CNS metastases will be excluded. If a participant has a known history of treated CNS lesions, they are eligible provided that all of the following criteria are met:
- Measurable disease, per RECIST v1.1, must be present outside the CNS.
- The participant has no history of intracranial hemorrhage or spinal cord hemorrhage.
- Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord).
- There is no evidence of interim progression between completion of CNS-directed therapy and the screening brain scan
- The participant has not received stereotactic radiotherapy within 7 days prior to initiation of study treatment or whole-brain radiotherapy within 14 days prior to initiation of study treatment.
- The participant has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted. Asymptomatic patients with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy or surgery, with no need to repeat the screening brain scan.
- History of leptomeningeal disease.
Uncontrolled tumor-related pain.
- NOTE: Participants requiring pain medication must be on a stable regimen at study entry.
- Symptomatic lesions amendable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should be treated prior to enrollment. Participants should be recovered from the effects of radiation. There is no required minimum recovery period.
- Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab and/or bevacizumab.
- Uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN)
Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome,Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions:
- Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
- Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
- Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met: Rash must cover <10% of body surface area, Disease is well controlled at baseline and requires only low-potency topical corticosteroids, No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet. A radiation, methotrexate,retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- Participants who test positive for HIV at time of screening are ineligible because of the increased risk of lethal infections when treated with marrow-suppressive therapy.
- Active hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test at screening. Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening are eligible for the study.
- Active hepatitis C virus (HCV) infection, defined as a positive HCV antibody test followed by a positive HCV RNA test at screening. The HCV RNA test will be performed only for participants who have a positive HCV antibody test.
- Participants with active tuberculosis will be excluded.
- Significant cardiovascular disease, such as a New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
- Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study.
- History of other malignancy within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
- Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
- Prior allogeneic stem cell or solid organ transplantation.
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the last dose of atezolizumab.
- Treatment with investigational therapy within 28 days prior to initiation of study treatment.
- Prior treatment with bevacizumab or prior PD-L1 targeted therapy.
- Treatment with systemic immunostimulatory agents (including, but not limited to,interferon and interleukin 2 [IL-2]) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to initiation of study treatment.
Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study, with the following exceptions:
- Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g. 48 hours of corticosteroids for a contrast allergy) are eligible for the study.
- Patients on physiologic replacement doses of steroids less than 10mg daily prednisone equivalent are allowed. Higher replacement doses should be discussed with the overall PI to determine if patient can be included on the trial.
- Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
- Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation.
- Known allergy or hypersensitivity to any component of the bevacizumab formulation.
- Inadequately controlled arterial hypertension (defined as systolic blood pressure [BP] > 150 mm Hg and/or diastolic BP >100 mmHg), based on an average of at least three BP readings at two or more sessions. Anti-hypertensive therapy to achieve these parameters is allowed.
- History of hypertensive crisis or hypertensive encephalopathy.
- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1 Day 1.
- History of hemoptysis (≥ 2.5 mL of bright red blood per episode) within 1 month prior to Cycle 1 Day 1.
- Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
- Current or recent (within 10 days of Cycle 1 Day 1) use of aspirin (> 325 mg/day) or current or recent treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
- Current or recent (within 10 days prior to Cycle 1 Day 1) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purpose (as opposed to prophylactic). Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR < 1.5 x ULN and aPTT is within normal limits (according to the institutional standards) within 14 days prior to Cycle 1 Day 1. Prophylactic use of low-molecular weight heparin (LMWH) (i.e., enoxaparin 40 mg/day) is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk.
- History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to Cycle 1 Day 1.
- Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure.
- Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture.
- Major surgical procedure within 4 weeks prior to Cycle 1 Day 1 or anticipation of need for a major surgical procedure during the study.
- History of intra-abdominal inflammatory process within 6 months prior to Cycle 1 Day 1, including, but not limited to, peptic ulcer disease, diverticulitis, or colitis.
- Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID).
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the last dose of atezolizumab and 6 months after the last dose of bevacizumab. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atezolizumab and Bevacizumab
The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.
Treatment will be administered on an outpatient basis Study treatment will continue until study doctors decide to stop therapy due to criteria which may include disease progression, adverse events or changes in condition. Participants will be followed for survival health information following treatment until the study ends, which could be approximately 5 years from start of treatment |
Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
Other Names:
Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate in PD-L1 negative melanoma
Time Frame: 5 Years
|
The primary endpoint for this study is overall response rate in PDL1 negative melanoma to combination anti-PD-L1 therapy and anti-VEGF therapy by RECIST criteria.
The proportion of patients with complete response or partial response as best response to therapy will be summarized and presented with a two-sided, 90% Wald confidence interval.
|
5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: start of treatment and death from any cause up to 5 years
|
Time from start of treatment to death
|
start of treatment and death from any cause up to 5 years
|
Time to tumor progression
Time Frame: up to 5 years
|
Time to tumor progression (TTP) is the time interval between the dates of the start of trial treatment and first documentation of progressive disease
|
up to 5 years
|
Duration of response
Time Frame: patients with objective response (confirmed CR or PR as best overall response) as the interval between dates of first documentation of objective response and first documentation of progressive disease up to 5 years
|
The time-to-event endpoints will each be summarized using the method of KaplanMeier Point estimates for each endpoint will be presented with 90% confidence intervals derived using log(-log(endpoint)) methodology.
|
patients with objective response (confirmed CR or PR as best overall response) as the interval between dates of first documentation of objective response and first documentation of progressive disease up to 5 years
|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE 5.
Time Frame: initiation of study treatment, during study treatment, and 30 days after the last dose of study treatment or study discontinuation/termination, whichever occurs first up to 5 years
|
Adverse events
|
initiation of study treatment, during study treatment, and 30 days after the last dose of study treatment or study discontinuation/termination, whichever occurs first up to 5 years
|
Change tumor-infiltrating lymphocytes (TILs)
Time Frame: baseline and progression/treatment discontinuation up to 5 years
|
Pre-treatment percentages of stromal infiltrating lymphocytes will be summarized descriptively for the two response groups and compared using Wilcoxon rank-sum tests. Changes in TILs between baseline and progression/treatment discontinuation will be calculated (post-pre) for each patient and summarized descriptivelyChanges in TILs between baseline and progression/treatment discontinuation will be calculated (post-pre) for each patient and summarized descriptively |
baseline and progression/treatment discontinuation up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Buchbinder, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Skin Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Immune Checkpoint Inhibitors
- Bevacizumab
- Atezolizumab
Other Study ID Numbers
- 19-604
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Melanoma
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Stage IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7 | Stage III Acral... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedMetastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte Corporation; University of VirginiaCompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Yale UniversityNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
Clinical Trials on Atezolizumab
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Intergroupe Francophone de Cancerologie ThoraciqueRoche Pharma AG; GFPCCompletedSmall Cell Lung CancerFrance
-
Yonsei UniversityNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
First Affiliated Hospital of Zhejiang UniversityHoffmann-La Roche; Geneplus-Beijing Co. Ltd.UnknownNon-Small Cell Lung CancerChina
-
Corvus Pharmaceuticals, Inc.Genentech, Inc.CompletedRenal Cell Cancer | Metastatic Castration Resistant Prostate CancerUnited States, Canada, Australia
-
Seoul National University HospitalUnknown
-
Incyte CorporationHoffmann-La Roche; Genentech, Inc.TerminatedUC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)United States
-
Chonnam National University HospitalRoche Pharma AGCompletedLung Neoplasm MalignantKorea, Republic of
-
University Medical Center GroningenHoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...WithdrawnDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedNetherlands
-
University Medical Center GroningenTerminatedLobular Metastatic Breast CancerNetherlands